NATCOPHARM Q4 Results FY26 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 28, 2026 3 min read

Natco Pharma enters its Q4 earnings print following a period of significant portfolio diversification, including the high-profile launch of generic Semaglutide in India and the strategic acquisition of a stake in South Africa's Adcock Ingram. Investors will be focused on whether these new growth drivers can offset the anticipated decline in Revlimid-related earnings and how the company manages margin pressures in an increasingly competitive domestic landscape.

Quick Details

Results date	May 29, 2026
Quarter	Q4 FY 2025-2026
Previous quarter revenue	705.4
Previous quarter PAT	151.3
Previous quarter EBITDA margin	30.7%
Market cap	Rs. 20990.72 Cr
CMP	Rs. 1170.3

NATCOPHARM Q4 Results Date and Time

The Board Meeting is scheduled for May 29, 2026, to consider and approve the audited financial results for Q4 & FY ending Mar 31, 2026.

An earnings conference call is scheduled for May 29, 2026, to discuss the audited Q4 & FY2026 results.

Key Things To Watch

Performance vs Guidance Tracking

FY26 Revenue — Rs. 4,200 to Rs. 4,300 Cr — 9M FY26 achieved Rs. 3,559 Cr
FY26 PAT — Rs. 1,280 to Rs. 1,300 Cr — Pending Q4 confirmation
Domestic Business — >20% growth — Driven by Semaglutide launch
Non-US Export Formulations — Rs. 800 to Rs. 900 Cr — Driven by new launches in Brazil, Canada, and Middle East

Semaglutide Market Strategy

Actual revenue uptake against the management-estimated Rs. 80-90 Cr incremental target
Management anticipates extreme competition with 10 to 15 generics expected in the Indian market
Fill-finish operations outsourced to OneSource to manage supply chain requirements

US Portfolio and Revlimid Impact

Management confirmed the December quarter was the first without substantial Revlimid revenue
Pomalidomide Capsules launched March 3, 2026, targeting a USD 3.2 billion US market
Management aims for 7-8 US filings in the next fiscal year

Risks and Headwinds to Monitor

Chennai API unit received VAI classification from USFDA with 7 observations in Form 483
NPPA demand notice received May 15, 2026, for Rs. 4,92,25,923 regarding alleged drug overcharging

Frequently Asked Questions

How does Natco Pharma plan to account for its investment in Adcock Ingram?

The 35.75% stake in Adcock Ingram will be recorded as a long-term investment under non-current assets. Profits will be recognized as an associate with a small element of goodwill amortization.

Why did management decline to provide specific FY27 guidance?

Management cited numerous moving parts, such as Para IV approvals and the phase transitions of Semaglutide, as reasons to defer specific figures. They have promised finalized guidance in the upcoming May call.

What is the status of the company's USFDA regulatory compliance?

The Chennai API unit received an Establishment Inspection Report (EIR) from the USFDA with a Voluntary Action Indicated (VAI) classification. This report contained 7 observations in Form 483.

Is the company on track to meet its FY26 revenue guidance?

With 9M FY26 revenue reaching Rs. 3,559 Cr against the full-year guidance of Rs. 4,200–4,300 Cr, the company requires a Q4 performance of Rs. 700-750 Cr to align with its target.